Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9870
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasticity; and neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc (ACOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Venture Financing 15
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Private Equity 19
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Equity Offering 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Debt Offering 29
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Asset Transactions 33
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Acquisition 34
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc – Key Competitors 40
Acorda Therapeutics Inc – Key Employees 41
Acorda Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Strategy And Business Planning 44
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44
Financial Announcements 45
Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45
Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47
May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48
Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50
Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60
Corporate Communications 62
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62
Product News 63
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63
Clinical Trials 64
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc, Key Competitors 40
Acorda Therapeutics Inc, Key Employees 41
Acorda Therapeutics Inc, Subsidiaries 42

List of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Reinsurance Group of America Inc:企業の戦略・SWOT・財務分析
    Reinsurance Group of America Inc - Strategy, SWOT and Corporate Finance Report Summary Reinsurance Group of America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • I.Ceram SA (ALICR):医療機器:M&Aディール及び事業提携情報
    Summary I.Ceram SA (I.Ceram) is a medical equipment and device company that designs, manufactures, and markets joint implants for neurosurgery and other surgical procedures. The company’s products include bone fillers, alumina bio-ceramic implants, trepan caps, cervical plates and blocks for cervica …
  • OJSC AK BARS Bank:企業の戦略・SWOT・財務情報
    OJSC AK BARS Bank - Strategy, SWOT and Corporate Finance Report Summary OJSC AK BARS Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Intec Pharma ltd (NTEC):企業の財務・戦略的SWOT分析
    Summary Intec Pharma Ltd (Intec Pharma) is a biopharmaceutical company that offers delivery solutions for drugs. The company’s pipeline products include drug indications for Parkinson’s disease, insomnia and other diseases. Its proprietary gastro retentive formulation, offers a drug delivery solutio …
  • Ultrapar Participacoes SA (UGPA3):企業の財務・戦略的SWOT分析
    Ultrapar Participacoes SA (UGPA3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • MIE Holdings Corp (1555):石油・ガス:M&Aディール及び事業提携情報
    Summary MIE Holdings Corp (MIEH), a subsidiary of Far East Energy Ltd is an oil and gas company that carries out exploration, development and production activities. The company operates Daan, Moliqing and Miao 3 oilfields in the Songliao Basin. Its Daan oilfield is located in Daan City that covers a …
  • Cheil Worldwide Inc. (030000):企業の財務・戦略的SWOT分析
    Cheil Worldwide Inc. (030000) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • SK Networks Co Ltd (001740):企業の財務・戦略的SWOT分析
    Summary SK Networks Co Ltd (SK Networks) is a marketing and distribution company. The company operates in diversified businesses including ICT marketing, automotive, hotel and resorts, rental appliances, and chemical material. It offers global trading in industrial materials such as steel, chemicals …
  • Commerzbank AG:戦略・SWOT・企業財務分析
    Commerzbank AG - Strategy, SWOT and Corporate Finance Report Summary Commerzbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • TransAlta Renewables Inc (RNW):電力:M&Aディール及び事業提携情報
    Summary TransAlta Renewables Inc (TransAlta Renewables), a subsidiary of TransAlta Corp, is a renewable energy company that operates and develops hydropower, wind power, and gas power generation facilities. The company develops, owns, operates, and maintains a fleet of power generation assets in Can …
  • Congenica Ltd-医療機器分野:企業M&A・提携分析
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers research and experimental development on biotechnology. The company’s technology SAPIENTIA, is used to personalize patient care through accurate diagnoses, support clinical trials, and drug development. It offers services such …
  • Banco Santander SA:企業の戦略・SWOT・財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • UbiQ Bio BV:製薬・医療:M&Aディール及び事業提携情報
    Summary UbiQ Bio BV (UbiQ) is a biotechnology company that develops and commercializes ubiquitinated peptides and assays that enables drug discovery in Ubiquitin field. The company provides products such as ubiquitin-proteasome system, high throughput screening assay reagents and ubiquitinated polyp …
  • Banco Cooperativo Espanol S.A.:企業の戦略・SWOT・財務分析
    Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Cooperativo Espanol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Shinkin Central Bank:企業の戦略・SWOT・財務情報
    Shinkin Central Bank - Strategy, SWOT and Corporate Finance Report Summary Shinkin Central Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Unicharm Corporation (8113):企業の財務・戦略的SWOT分析
    Unicharm Corporation (8113) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Helix Energy Solutions Group Inc (HLX):石油・ガス:M&Aディール及び事業提携情報
    Summary Helix Energy Solutions Group Inc (Helix Energy) is an oil and gas company that provides offshore energy services. The company provides well intervention and subsea contracting services. It offers well intervention services comprise, riserless intervention operations, riser based operations, …
  • Oxford Metrics plc (OMG):企業の財務・戦略的SWOT分析
    Oxford Metrics plc (OMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nippon Chemi-Con Corporation (6997):企業の財務・戦略的SWOT分析
    Nippon Chemi-Con Corporation (6997) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆